



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

December 7, 2021: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**
  
- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**  
(Public Comment Prior to Board Action)
  
- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**
  
- **Medical Director Update** **6:45 - 6:50**
  
- **Follow-up Items from Previous Meetings** **6:50 – 7:00**
  - Codeine Use in Pediatric Patients
  
- **RetroDUR/ProDUR** **7:00- 7:20**
  - Introduce: Blood Glucose Test Strips in CGM Users
  - Data presentation: Use of Acute Migraine Treatments After CGRP Initiation
  
- **Clinical Update: Drug Reviews** **7:20-7:55**  
(Public comment prior to Board action)

**Biosimilar Drug Reviews**

- None at this time.

**Full New Drug Reviews**

(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)

- Elepsia XR® (Levetiracetam extended-release)
  - Empaveli® (pegcetacoplan)
  - Exservan® (riluzole)
  - Myfembree® (relugolix, estradiol and norethindrone acetate)
  - Nextstellis® (drospirenone/estetrol)
  - Ozobax® (baclofen oral solution)
  - Qelbree® (viloxazine extended-release)
  - Zegalogue® (daiglucagon)
- 
- **New Managed Therapeutic Drug Classes** **7:55 -7:55**
    - None at this time

(Public comment prior to Board action)

- None at this time
  
- **Therapeutic Drug Classes – Periodic Review** **7:55 - 8:25**  
(Public comment prior to Board action)
  - Anticoagulants
  - Antidepressants, Other
  - Antidepressants, SSRIs
  - Antiparkinson’s Agents
  - Gastrointestinal Agents (H2 blockers, PPIs)
  - H. Pylori Agents
  - Hyperuricemia and Gout
  - Platelet Aggregation Inhibitors
  
- **Review of Newly Developed/Revised Criteria** **8:25 - 8:30**  
(Public comment prior to Board action)
  - Hepatitis C Agents
  
- **General Announcements** **8:30 – 8:30**
  
- **Adjourn** **8:30**